Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Simvastatin and Diastolic Dysfunction

This study has been completed.
Fundação de Amparo a Pesquisa do Distrito Federal
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Information provided by:
Brasilia Heart Study Group Identifier:
First received: February 2, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted

Diastolic dysfunction (DD) is an increasingly frequent condition in hypertensive individuals whose treatment remains unclear. Its presence is related to higher morbidity and mortality independent of blood pressure levels. The aim of this study is to investigate the additive effect of simvastatin on enalapril on DD in hypertensive patients with average cholesterol levels.

For this aim, hypertensive patients with DD and LDL-cholesterol <160 mg/dL will undergo a run-in phase to achieve a systolic blood pressure (SBP) <135 mmHg and diastolic blood pressure (DBP) <85 mmHg with enalapril. Hydrochlorothiazide could be added when need to achieve SBP or DBP control. Four weeks after reaching the optimum anti-hypertensive regimen patients will be randomized to receive 80 mg simvastatin or placebo for a period of 20 weeks. Echocardiograms will be performed before and after treatment with measurement of left atrial volume, conventional and tissue Doppler velocities in early diastole and late diastole. The evaluation of these will allow to identify changes of DD severity after treatment.

Condition Intervention Phase
Diastolic Dysfunction
Drug: Simvastatin
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of the Addition of Simvastatin to Enalapril in Hypertensive Individuals With Average Cholesterol Levels and Diastolic Dysfunction

Resource links provided by NLM:

Further study details as provided by Brasilia Heart Study Group:

Primary Outcome Measures:
  • Changes in E/A ratio and e' wave velocity [ Time Frame: 20 weeks ]

Secondary Outcome Measures:
  • Changes in left atrium volume. [ Time Frame: 20 weeks ]
  • Changes in left ventricular mass. [ Time Frame: 20 weeks ]
  • Changes in e´/a´ waves ratio. [ Time Frame: 20 weeks ]
  • Changes in mitral deceleration time. [ Time Frame: 20 weeks ]
  • Changes in the ratio of mitral inflow velocity to annular relaxation velocity. [ Time Frame: 20 weeks ]
  • Changes in mitral annulus systolic velocity [ Time Frame: 20 weeks ]
  • Diastolic function reserve index measured at peak stress with dobutamine [ Time Frame: 20 weeks ]

Enrollment: 55
Study Start Date: November 2006
Study Completion Date: August 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Drug: Placebo
1 pill once a day
Experimental: Simvastatin
Simvastatin 80 mg/day
Drug: Simvastatin
80 mg once a day
Other Name: Zocor


Ages Eligible for Study:   40 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • men or postmenopausal women aged between 40 and 65 years old
  • normal fasting blood glucose (<100 mg/dL) and glucose tolerance test (<140 mg/dL)
  • waist circumference < 102 cm (men) or < 88cm (women)
  • triglycerides <150 mg/dL, LDL cholesterol ≤ 160 mg/dl
  • creatinine <1.2 mg/dL, sinus rhythm
  • the presence of grade 1 or 2 of DD with an ejection fraction of left ventricle > 55%
  • absence of myocardial ischemia during dobutamine stress echocardiography

Exclusion Criteria:

  • thyroid dysfunction
  • acute or chronic liver disease
  • regular use of 3 or more antihypertensive drugs
  • secondary hypertension
  • symptoms or history of atherosclerotic disease
  • valvular dysfunction
  • LVH 14 and use of statins in the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01061450

Instituto de Cardiologia do Distrito Federal
Brasilia, DF, Brazil, 70000.000
Sponsors and Collaborators
Brasilia Heart Study Group
Fundação de Amparo a Pesquisa do Distrito Federal
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Principal Investigator: Adenalva LS Beck, MD InCor Heart Institute
Study Chair: Andrei C Sposito, MD, PhD University of Brasilia Medical School, Brasilia, Brazil
Principal Investigator: Maria E Otto, MD, PhD Instituto de Cardiologia do Distrito Federal, Brasilia, Brazil
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Andrei C Sposito, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil Identifier: NCT01061450     History of Changes
Other Study ID Numbers: Statin_DD
Study First Received: February 2, 2010
Last Updated: February 2, 2010

Keywords provided by Brasilia Heart Study Group:
Diastolic dysfunction
ACE inhibitor

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on April 25, 2017